vs
豪洛捷（HOLX）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是豪洛捷的1.3倍（$1.4B vs $1.0B），豪洛捷净利率更高（17.1% vs 5.8%，领先11.3%），ROKU, INC同比增速更快（16.1% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $106.6M），过去两年ROKU, INC的营收复合增速更高（25.8% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
HOLX vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.3倍
$1.0B
营收增速更快
ROKU
高出13.6%
2.5%
净利率更高
HOLX
高出11.3%
5.8%
自由现金流更多
HOLX
多$108.6M
$106.6M
两年增速更快
ROKU
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.4B |
| 净利润 | $179.1M | $80.5M |
| 毛利率 | 56.0% | 43.5% |
| 营业利润率 | 22.6% | 4.7% |
| 净利率 | 17.1% | 5.8% |
| 营收同比 | 2.5% | 16.1% |
| 净利润同比 | -10.9% | 326.4% |
| 每股收益（稀释后） | $0.79 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXROKU
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.0B | $1.0B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $988.0M | $1.1B | ||
| Q2 24 | $1.0B | $968.2M | ||
| Q1 24 | $1.0B | $881.5M |
净利润HOLXROKU
| Q4 25 | $179.1M | $80.5M | ||
| Q3 25 | $187.2M | $24.8M | ||
| Q2 25 | $194.9M | $10.5M | ||
| Q1 25 | $-17.4M | $-27.4M | ||
| Q4 24 | $201.0M | $-35.5M | ||
| Q3 24 | $178.6M | $-9.0M | ||
| Q2 24 | $194.5M | $-34.0M | ||
| Q1 24 | $169.9M | $-50.9M |
毛利率HOLXROKU
| Q4 25 | 56.0% | 43.5% | ||
| Q3 25 | 55.6% | 43.4% | ||
| Q2 25 | 56.3% | 44.8% | ||
| Q1 25 | 37.5% | 43.6% | ||
| Q4 24 | 56.8% | 42.7% | ||
| Q3 24 | 56.4% | 45.2% | ||
| Q2 24 | 55.4% | 43.9% | ||
| Q1 24 | 53.3% | 44.1% |
营业利润率HOLXROKU
| Q4 25 | 22.6% | 4.7% | ||
| Q3 25 | 22.6% | 0.8% | ||
| Q2 25 | 24.9% | -2.1% | ||
| Q1 25 | -0.7% | -5.7% | ||
| Q4 24 | 22.5% | -3.3% | ||
| Q3 24 | 23.3% | -3.4% | ||
| Q2 24 | 24.1% | -7.4% | ||
| Q1 24 | 20.7% | -8.2% |
净利率HOLXROKU
| Q4 25 | 17.1% | 5.8% | ||
| Q3 25 | 17.8% | 2.0% | ||
| Q2 25 | 19.0% | 0.9% | ||
| Q1 25 | -1.7% | -2.7% | ||
| Q4 24 | 19.7% | -3.0% | ||
| Q3 24 | 18.1% | -0.9% | ||
| Q2 24 | 19.2% | -3.5% | ||
| Q1 24 | 16.7% | -5.8% |
每股收益（稀释后）HOLXROKU
| Q4 25 | $0.79 | $0.55 | ||
| Q3 25 | $0.84 | $0.16 | ||
| Q2 25 | $0.86 | $0.07 | ||
| Q1 25 | $-0.08 | $-0.19 | ||
| Q4 24 | $0.87 | $-0.24 | ||
| Q3 24 | $0.75 | $-0.06 | ||
| Q2 24 | $0.82 | $-0.24 | ||
| Q1 24 | $0.72 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $2.3B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $2.7B |
| 总资产 | $9.2B | $4.4B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXROKU
| Q4 25 | $2.4B | $2.3B | ||
| Q3 25 | $2.2B | $2.3B | ||
| Q2 25 | $1.9B | $2.3B | ||
| Q1 25 | $1.6B | $2.3B | ||
| Q4 24 | $2.0B | $2.2B | ||
| Q3 24 | $2.3B | $2.1B | ||
| Q2 24 | $2.4B | $2.1B | ||
| Q1 24 | $2.2B | $2.1B |
总债务HOLXROKU
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
股东权益HOLXROKU
| Q4 25 | $5.2B | $2.7B | ||
| Q3 25 | $5.0B | $2.6B | ||
| Q2 25 | $4.8B | $2.6B | ||
| Q1 25 | $4.6B | $2.5B | ||
| Q4 24 | $4.8B | $2.5B | ||
| Q3 24 | $5.1B | $2.5B | ||
| Q2 24 | $5.0B | $2.4B | ||
| Q1 24 | $4.8B | $2.4B |
总资产HOLXROKU
| Q4 25 | $9.2B | $4.4B | ||
| Q3 25 | $9.0B | $4.4B | ||
| Q2 25 | $8.8B | $4.3B | ||
| Q1 25 | $8.5B | $4.2B | ||
| Q4 24 | $8.7B | $4.3B | ||
| Q3 24 | $9.2B | $4.3B | ||
| Q2 24 | $8.9B | $4.1B | ||
| Q1 24 | $8.7B | $4.2B |
负债/权益比HOLXROKU
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $107.7M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $106.6M |
| 自由现金流率自由现金流/营收 | 20.5% | 7.6% |
| 资本支出强度资本支出/营收 | 1.4% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.28× | 1.34× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $478.4M |
8季度趋势，按日历期对齐
经营现金流HOLXROKU
| Q4 25 | $229.9M | $107.7M | ||
| Q3 25 | $355.1M | $127.6M | ||
| Q2 25 | $343.3M | $109.7M | ||
| Q1 25 | $169.4M | $138.7M | ||
| Q4 24 | $189.3M | $79.3M | ||
| Q3 24 | $367.0M | $68.7M | ||
| Q2 24 | $405.8M | $23.4M | ||
| Q1 24 | $292.4M | $46.7M |
自由现金流HOLXROKU
| Q4 25 | $215.2M | $106.6M | ||
| Q3 25 | $341.4M | $126.5M | ||
| Q2 25 | $330.5M | $108.6M | ||
| Q1 25 | $153.9M | $136.8M | ||
| Q4 24 | $172.5M | $76.8M | ||
| Q3 24 | $350.6M | $67.6M | ||
| Q2 24 | $385.3M | $22.5M | ||
| Q1 24 | $279.6M | $46.0M |
自由现金流率HOLXROKU
| Q4 25 | 20.5% | 7.6% | ||
| Q3 25 | 32.5% | 10.4% | ||
| Q2 25 | 32.3% | 9.8% | ||
| Q1 25 | 15.3% | 13.4% | ||
| Q4 24 | 16.9% | 6.4% | ||
| Q3 24 | 35.5% | 6.4% | ||
| Q2 24 | 38.1% | 2.3% | ||
| Q1 24 | 27.5% | 5.2% |
资本支出强度HOLXROKU
| Q4 25 | 1.4% | 0.1% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.3% | 0.1% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 1.7% | 0.1% | ||
| Q2 24 | 2.0% | 0.1% | ||
| Q1 24 | 1.3% | 0.1% |
现金转化率HOLXROKU
| Q4 25 | 1.28× | 1.34× | ||
| Q3 25 | 1.90× | 5.14× | ||
| Q2 25 | 1.76× | 10.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ROKU
| Services | $1.2B | 88% |
| Products | $170.9M | 12% |
